Monitor for future enrollment updates and interim data readouts from the IMPROVE-PAH trial, which could serve as catalysts for the stock. The progression to Phase 3 represents derisking of the clinical program, but no commercial or financial implications are immediate.
Price Chart
Executive Summary
Inhibikase Therapeutics announced the enrollment of the first patient in its global Phase 3 IMPROVE-PAH trial for IKT-001, a treatment candidate for pulmonary arterial hypertension. This marks a key milestone in the drug's development pathway toward potential NDA submission.
Key Facts
- Inhibikase Therapeutics (IKT) enrolled the first patient in its Phase 3 IMPROVE-PAH study for IKT-001 in pulmonary arterial hypertension (PAH)
- The trial is a two-part adaptive study with approximately 140 patients in Part A and 346 in Part B
- Primary endpoints are change in Pulmonary Vascular Resistance (PVR) at Week 24 for Part A and change in 6-minute walk distance (6MWD) at Week 24 for Part B
- The study will be conducted at up to approximately 180 sites globally
- IKT-001 is a novel oral prodrug of imatinib mesylate designed to reduce gastrointestinal side effects
Financial Impact
No immediate financial impact disclosed; this is a clinical development milestone
Risk Factors
- Clinical trial may encounter safety or efficacy issues leading to discontinuation
- Enrollment may be slower than anticipated
- IKT-001 may not demonstrate sufficient benefit over existing PAH therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-144582 |
| Document: d108350dex991.htm | 0001193125-26-144582 |
| Document: 0001193125-26-144582-index-headers.html | 0001193125-26-144582 |
| Document: 0001193125-26-144582-index.html | 0001193125-26-144582 |
| Document: 0001193125-26-144582.txt | 0001193125-26-144582 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K | $1.66 | awaiting T+20 | — | $1.57 (−5.42%) |
Oct 2, 2026 25d ago | Press Release | $2.00 | awaiting T+20 | — | $1.57 (−21.50%) |
Aug 11, 2026 11w ago | Press Release | $2.40 $2.33 | ▼ −2.92% | ▼ −1.02% | $1.57 (−34.58%) |
Jul 23, 2026 13w ago | 8-K | $2.33 $2.35 | ▲ +0.86% | ▼ −2.45% | $1.57 (−32.62%) |
Jul 17, 2026 14w ago | 3 | $2.23 $2.39 | ▲ +7.17% | ▲ +3.05% | $1.57 (−29.60%) |
Jul 14, 2026 15w ago | 8-K | $2.06 $2.45 | ▼ −18.93% | ▼ −16.44% | $1.57 (+23.79%) |
Jun 29, 2026 17w ago | 8-K | $1.93 $2.33 | ▲ +20.73% | ▲ +21.00% | $1.57 (−18.65%) |
May 12, 2026 24w ago | 8-K | $1.90 $1.67 | ▼ −12.11% | ▼ −11.49% | $1.57 (−17.37%) |
May 12, 2026 24w ago | Press Release | $1.90 $1.67 | ▼ −12.11% | ▼ −11.49% | $1.57 (−17.37%) |
Apr 7, 2026 29w ago | 8-K | $1.76 $1.94 | ▲ +10.23% | ▲ +0.45% | $1.57 (−10.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers